Charles River Laboratories International, Inc. Stock Xetra
Equities
RV6
US1598641074
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
200.9 EUR | -6.93% | 0.00% | 0.00% |
Sales 2024 * | 4.22B 3.89B | Sales 2025 * | 4.53B 4.18B | Capitalization | 11.21B 10.34B |
---|---|---|---|---|---|
Net income 2024 * | 406M 375M | Net income 2025 * | 513M 473M | EV / Sales 2024 * | 3.12 x |
Net Debt 2024 * | 1.94B 1.79B | Net Debt 2025 * | 1.46B 1.34B | EV / Sales 2025 * | 2.8 x |
P/E ratio 2024 * |
27.5
x | P/E ratio 2025 * |
22.3
x | Employees | 21,100 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.93% |
Latest transcript on Charles River Laboratories International, Inc.
1 day | -6.93% |
Managers | Title | Age | Since |
---|---|---|---|
James Foster
CEO | Chief Executive Officer | 73 | 75-12-31 |
Flavia Pease
DFI | Director of Finance/CFO | 51 | 22-04-24 |
Birgit Girshick
COO | Chief Operating Officer | 54 | 89-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
George Massaro
BRD | Director/Board Member | 76 | 02-12-31 |
Virginia Wilson
BRD | Director/Board Member | 68 | 19-09-30 |
Robert Bertolini
BRD | Director/Board Member | 61 | 11-01-24 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+64.92% | 62.86B | |
-1.85% | 41.38B | |
+45.77% | 40.38B | |
-8.93% | 27.64B | |
+13.05% | 26.46B | |
-21.96% | 18.9B | |
+4.21% | 12.67B | |
+25.74% | 12.27B | |
+27.42% | 12.07B |
- Stock Market
- Equities
- CRL Stock
- RV6 Stock